Orphan drug
Orphan Drug approval brings several benefits
Edvince has been granted Orphan Drug Designation for its first drug candidate, EDV2209, in both the EU and the USA. This is an important regulatory milestone that provides comprehensive protection and several strategic advantages ahead of the ongoing development and future commercialisation of the drug. The orphan designation is particularly important in the treatment of rare and serious diseases, and allows Edvince to combine regulatory support with strong market exclusivity.
Market exclusivity
During the protection period, no other operator is allowed to market a medication for the same indication, which in practice gives EDV2209 a unique position on the market. This exclusivity lasts for 10 years in the EU and 7 years in the USA, and is frequently stronger than patent protection.
Regulatory benefits
The orphan designation entails a number of incentives that can reduce development costs and speed up market approval. These include research grants, financial support, reduced or waived regulatory fees, as well as prioritised and faster processing by regulatory authorities. In addition, the classification contributes to increased visibility and support from the regulatory ecosystem.
Flexibility in clinical development
For medicines targeting rare diseases, more flexible requirements are applied in clinical trials, which might include smaller study populations and slightly more lenient efficacy criteria. This allows for a more efficient use of resources during the development programme.
Potential for higher pricing
As orphan drugs target small patient populations and often lack alternative treatment options, the opportunity exists for pricing that better reflects the medical benefit and development costs. This can contribute to a stronger long-term revenue base.
In summary, Orphan Drug Designation for EDV2209 provides Edvince with enhanced commercial and regulatory protection, at the same time as allowing for faster and more cost-effective development towards market launch.
Contact
Medicon Village
223 81 Lund. Sweden
info@edvince.com